Personalized and Precision Medicine Journal
Where Innovations Meets Personalized and Precision Medicine

Targeting Key Genes in the Early Diagnosis and Treatment of Lung Cancer with a Focus on Personalized Medicine: a Review Article

Document Type : Original Article

Authors

Milad Pezeshki 1
Abbas Ardalan 2
Mahdi Nakhaee 3
Saeid Ziaei 4
Roja Valipoor 5
Elahe Tamjidi 6
Rozhin Naseri 7

1 MSc in Genetics, Development and Research Group of LifeandMe Company, Tehran, Iran.

2 Science Based Amitis Gen Tech Dev Group, Tehran, Iran.

3 Expert in Laboratory Sciences, Development and Research Group of LifeandMe Company, Tehran, Iran

4 PhD of Applied Proteomics, Development and Research Group of LifeandMe Company, Tehran, Iran.

5 Department of Laboratory Medicine, Faculty of Paramedical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

6 MSc in Physiology Education and Sport Sciences, Shahid Chamran University, Ahvaz, Iran.

7 MSc Student in Cell and Molecular, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.

https://doi.org/10.22034/pmj.2024.713765
Abstract
IntroductionLung cancer is the prevailing form of cancer globally, with a significant fatality rate among both males and females. Lung cancer is the third most frequent type of cancer in Iran, and it is becoming more common all the time. Patients are frequently diagnosed in the advanced stages of the disease, which contributes to the high death rate. Therefore, the ability to identify molecular markers is essential for both early diagnosis and the choice of conventional treatment for lung cancer. Numerous genetic variations have been found to be strongly linked to the development of lung cancer, according to studies. The aim of this work is to look into the genes that contribute to the development of lung cancer.
Materials and methods: The present review was authored using search terms related to lung cancer, key genes, clinical biomarkers, and early diagnosis that were found on PubMed, NCBI, Scopus, Science Direct, and Google Scholar.
Findings: Since the EGFR, KRAS, BRAF, and TP53 genes are the most significant and involved in the development of lung cancer, finding mutations in these genes can be a valuable clinical diagnostic for lung cancer diagnosis and therapy.
Discussion and conclusion: With an emphasis on personalized medicine, the identification of genes linked to lung cancer may be utilized as clinical biomarkers for the disease's early diagnosis and effective treatment. The state of targeted lung cancer therapy and early detection techniques may be enhanced by molecular biomarkers. In the field of personalized medicine, identifying the genes linked to lung cancer as clinical biomarkers for early diagnosis and assessing treatment response to select a targeted treatment can be crucial in streamlining the therapeutic process, improving treatment response, lowering mortality, and lessening the material and spiritual harm this illness causes.

Keywords

lung cancer
key genes
clinical biomarkers
early diagnosis
Personalized medicine
  1. He J, Xi B, Ruiter R, Shi TY, Zhu ML, Wang MY, Li QX, Zhou XY, Qiu LX, Wei QY. Association of LEP G2548A and LEPR Q223R polymorphisms with cancer susceptibility: evidence from a meta-analysis. PloS one. 2013 Oct 17;8(10):e75135.
  2. Wadowska K, Bil-Lula I, Trembecki Ł, Śliwińska-Mossoń M. Genetic markers in lung cancer diagnosis: a review. International journal of molecular sciences. 2020 Jan;21(13):4569.
  3. Zhang Y, Zhang L, Li R, Chang DW, Ye Y, Minna JD, Roth JA, Han B, Wu X. Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility. Annals of Oncology. 2017 Apr 5;28(7):1625-30.
  4. Mustafa M, JamalulAzizi AR, IIIzam EL, Nazirah A, AM S, Abbas SA. Lung cancer: risk factors, management, and prognosis. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS). 2016;15(10).94-101.
  5. Zou S, Pan X, Hua C, Wu M, He B, Chen Z. Myeloperoxidase-463 G/A polymorphism is associated with lung cancer risk: A meta-analysis with 7420 cases and 9132 controls. Journal of cancer research and therapeutics. 2018 Jun 1;14(9):282.
  6. Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. Journal of Thoracic Oncology. 2016 Oct 1;11(10):1653-71.
  7. Dai X, Deng S, Wang T, Qiu G, Li J, Yang B, Feng W, He X, Deng Q, Ye J, Zhang W. Associations between 25 lung cancer risk-related SNPs and polycyclic aromatic hydrocarbon-induced genetic damage in coke oven workers. Cancer Epidemiology and Prevention Biomarkers. 2014 Apr 1:cebp-1251.
  8. Bashir N, Ragab E, Khabour O, Khassawneh B, Alfaqih M, Momani J. The association between epidermal growth factor receptor (EGFR) gene polymorphisms and lung cancer risk. Biomolecules. 2018 Sep;8(3):53.
  9. Dehghani M, Samani Z, Abidi H, Manzouri L, Mahmoudi R, Hosseini Teshnizi S, Nikseresht M. Relationship of SNP rs2645429 in Farnesyl-Diphosphate Farnesyltransferase 1 Gene Promoter with Susceptibility to Lung Cancer. International journal of genomics. 2018;2018.
  10. Khazaei S, Mansori K, Soheylizad M, Gholamaliee B, Shadmani FK, Khazaei Z, Ayubi E. Epidemiology of lung cancer in Iran: sex difference and geographical distribution. Middle East Journal of Cancer. 2017 Sep 16;8(4):223-8.
  11. Vardanjani HM, Zeinali M, Radmerikhi S, Hadipour M. Lung cancer prevalence in Iran by histologic subtypes. Advanced biomedical research. 2017;6.
  12. Byun J, Schwartz AG, Lusk C, Wenzlaff AS, de Andrade M, Mandal D, Gaba C, Yang P, You M, Kupert EY, Anderson MW. Genome-Wide Association Study of Familial Lung Cancer. Carcinogenesis. 2018 Jun 19.
  13. Kong J, Xu F, Qu J, Wang Y, Gao M, Yu H, Qian B. Genetic polymorphisms in the vitamin D pathway in relation to lung cancer risk and survival. Oncotarget. 2015 Feb;6(4):2573.
  14. Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M, Duan W, Zhou X, Liang R, Tao M. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget. 2015 Feb;6(5):3452.
  15. Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: functions and mechanisms. Chemical reviews. 2006 Feb 8;106(2):302-23.
  16. Dogan M, Demirkazik A, Tukun A, CEYHAN K, YALCIN B, AKBULUT H, Fikri IC. The relationship between common EGFR, BRAF, KRAS mutations and prognosis in advanced stage non-small cell lung cancer with response to the treatment in Turkey. International Journal of Hematology and Oncology. 2014 Jan 1;28(4):001-10.
  17. Li L, Guo G, Zhang H, Zhou B, Bai L, Chen H, Zhao Y, Yan Y. Association between H19 SNP rs217727 and lung cancer risk in a Chinese population: a case control study. BMC medical genetics. 2018 Dec;19(1):136.
  18. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, Berrettini W, Knouff CW, Yuan X, Waeber G, Vollenweider P. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nature genetics. 2010 May;42(5):436.
  19. Grosse A, Grosse C, Rechsteiner M, Soltermann A. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland. Diagnostic pathology. 2019 Dec;14(1):18.
  20. Al Dayel F. EGFR mutation testing in non-small cell lung cancer (NSCLC). Journal of infection and public health. 2012 Dec 1;5:S31-4.
  21. Choi HU, Mazzone P. Radon and lung cancer: assessing and mitigating the risk. Cleve Clin J Med. 2014 Sep 1;81(567):75.
  22. LIM WY, Seow A. Biomass fuels and lung cancer. Respirology. 2012 Jan;17(1):20-31.
  23. Sood A. Indoor fuel exposure and the lung in both developing and developed countries: an update. Clinics in chest medicine. 2012 Dec 1;33(4):649-65.
  24. Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May 1;143(5):e1S-29S.
  25. Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L. Preventable exposures associated with human cancers. Journal of the National Cancer Institute. 2011 Dec 12;103(24):1827-39.
  26. Jin G, Wang H, Hu Z, Liu H, Sun W, Ma H, Chen D, Miao R, Tian T, Jin L, Wei Q. Potentially functional polymorphisms of EXO1 and risk of lung cancer in a Chinese population: A case-control analysis. Lung cancer. 2008 Jun 1;60(3):340-6.
  27. Jo UH, Han SG, Seo JH, Park KH, Lee JW, Lee HJ, Ryu JS, Kim YH. The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population. BMC cancer. 2008 Dec;8(1):359.
  28. Rose-James A, TT S. Molecular markers with predictive and prognostic relevance in lung cancer. Lung cancer international. 2012;2012 .
  29. Rami-Porta R, Asamura H, Brierley J, Goldstraw P. Staging, tumor profile, and prognostic groups in lung cancer or the new tower of Babel. Journal of Thoracic Oncology. 2016 Aug 1;11(8):1201-3.
  30. Surdu S, Fitzgerald EF, Bloom MS, Boscoe FP, Carpenter DO, Haase RF, Gurzau E, Rudnai P, Koppova K, Vahter M, Leonardi G. Polymorphisms in DNA repair genes XRCC1 and XRCC3, occupational exposure to arsenic and sunlight, and the risk of non-melanoma skin cancer in a European case-control study. Environmental research. 2014 Oct 1;134:382-9.
  31. Timofeeva MN, Hung RJ, Rafnar T, Christiani DC, Field JK, Bickeböller H, Risch A, McKay JD, Wang Y, Dai J, Gaborieau V. Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Human molecular genetics. 2012 Aug 16;21(22):4980-95.
  32. Rafnar T, Sulem P, Besenbacher S, Gudbjartsson DF, Zanon C, Gudmundsson J, Stacey SN, Kostic JP, Thorgeirsson TE, Thorleifsson G, Bjarnason H. Genome-wide significant association between a sequence variant at 15q15. 2 and lung cancer risk. Cancer research. 2011 Feb 8.
  33. Truong T, Sauter W, McKay JD, Hosgood III HD, Gallagher C, Amos CI, Spitz M, Muscat J, Lazarus P, Illig T, Wichmann HE. International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants. Carcinogenesis. 2010 Jan 27;31(4):625-33.
  34. Hsu NY, Wang HC, Wang CH, Chiu CF, Tseng HC, Liang SY, Tsai CW, Lin CC, Bau DT. Lung cancer susceptibility and genetic polymorphisms of Exo1 gene in Taiwan. Anticancer research. 2009 Feb 1;29(2):725-30.
  35. Feng X, Qin JJ, Zheng BS, Huang LL, Xie XY, Zhou HF. Association of epidermal growth factor receptor (EGFR) gene polymorphism with lung cancer risk: a systematic review. Journal of Receptors and Signal Transduction. 2014 Oct 1;34(5):333-4.
  36. Ribeiro R, Araújo AP, Coelho A, Catarino R, Pinto D, Araújo A, Calçada C, Lopes C, Medeiros R. A functional polymorphism in the promoter region of leptin gene increases susceptibility for non-small cell lung cancer. European Journal of Cancer. 2006 May 1;42(8):1188-93.
  37. Li Y, Chang SC, Niu R, Liu L, Crabtree-Ide CR, Zhao B, Shi J, Han X, Li J, Su J, Cai L. TP53 genetic polymorphisms, interactions with lifestyle factors and lung cancer risk: a case control study in a Chinese population. BMC cancer. 2013 Dec;13(1):607.
  38. Zhang M, Zhao D, Yan C, Zhang L, Liang C. Associations between nine polymorphisms in EXO1 and cancer susceptibility: a systematic review and meta-analysis of 39 case-control studies. Scientific reports. 2016 Jul 8;6:29270.
  39. Duarte RL, Paschoal ME. Molecular markers in lung cancer: prognostic role and relationship to smoking. Jornal Brasileiro de Pneumologia. 2006 Feb;32(1):56-65. .
  40. El-Telbany A, Ma PC. Cancer genes in lung cancer: racial disparities: are there any?. Genes & cancer. 2012 Jul;3(7-8):467-80.
  41. Carper MB, Claudio PP. Clinical potential of gene mutations in lung cancer. Clinical and translational medicine. 2015 Dec;4(1):33.
  42. Kanwal M, Ding XJ, Cao Y. Familial risk for lung cancer. Oncology letters. 2017 Feb 1;13(2):535-42. .
  43. Acquaviva J, Smith DL, Sang J, Friedland JC, He S, Sequeira M, Zhang C, Wada Y, Proia DA. Targeting KRAS-mutant non–small cell lung cancer with the Hsp90 inhibitor ganetespib. Molecular cancer therapeutics. 2012 Dec 1;11(12):2633-43.
  44. Torres-Jasso JH, Marín ME, Santiago-Luna E, Leoner JC, Torres J, Magaña-Torres MT, Perea FJ, Ibarra B, Sánchez-López JY. EGFR gene polymorphisms-216G> T and-191C> A are risk markers for gastric cancer in Mexican population. Genet Mol Res. 2015 Jan 1;14:1802-7.
  45. Guntur VP, Waldrep JC, Guo JJ, Selting K, Dhand R. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Anticancer research. 2010 Sep 1;30(9):3557-64.
  46. Weart TC, Miller KD, Simone 2nd CB. Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy. Cancer management and research. 2018;10:647.
  47. Stoehlmacher-Williams J, Obermann L, Ehninger G, Goekkurt E. Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC). Anticancer research. 2012 Feb 1;32(2):421-5.
  48. Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers. 2017 May;9(5):52.
  49. Martínez-Carretero C, Pascual FI, Rus A, Bernardo I. Detection of EGFR mutations in patients with non-small cell lung cancer by high resolution melting. Comparison with other methods. Clinical Chemistry and Laboratory Medicine (CCLM). 2017 Oct 26;55(12):1970-8.
  50. Yamamoto G, Kikuchi M, Kobayashi S, Arai Y, Fujiyoshi K, Wakatsuki T, Kakuta M, Yamane Y, Iijima Y, Mizutani H, Nakajima Y. Routine genetic testing of lung cancer specimens derived from surgery.
  51. Inamura K, Ninomiya H, Ishikawa Y, Matsubara O. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?. Archives of pathology & laboratory medicine. 2010 Jan;134(1):66-72.
  52. Li S, Li L, Zhu Y, Huang C, Qin Y, Liu H, Ren-Heidenreich L, Shi B, Ren H, Chu X, Kang J. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. British journal of cancer. 2014 May;110(11):2812.
  53. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Modern pathology. 2008 Apr 25;21(S2):S16.
  54. Wu SG, Hu FC, Chang YL, Lee YC, Yu CJ, Chang YC, Wu JY, Shih JY, Yang PC. Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. European Respiratory Journal. 2013 Feb 1;41(2):417-24.
  55. Lazarus DR, Ost DE. How and when to use genetic markers for non-small cell lung cancer. Current opinion in pulmonary medicine. 2013 Jul;19(4):331.
  56. Guo H, Xing Y, Liu R, Chen S, Bian X, Wang F, Yang C, Wang X. -216G/T (rs712829), a functional variant of the EGFR promoter, is associated with the pleural metastasis of lung adenocarcinoma. Oncology letters. 2013 Sep 1;6(3):693-8.
  57. Cruz-Lopez O, Conejo-García A, C Nunez M, Kimatrai M, E Garcia-Rubino M, Morales F, Gomez-Perez V, M Campos J. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors. Current medicinal chemistry. 2011 Mar 1;18(7):943-63.
  58. Martin P, Leighl NB, Tsao MS, Shepherd FA. KRAS mutations as prognostic and predictive markers in non–small cell lung cancer. Journal of Thoracic Oncology. 2013 May 1;8(5):530-42. .
  59. Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, Murphy KM. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. The Journal of Molecular Diagnostics. 2010 Jul 1;12(4):425-32.
  60. Román M, Baraibar I, López I, Nadal E, Rolfo C, Vicent S, Gil-Bazo I. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Molecular cancer. 2018 Dec;17(1):33.
  61. Ferrer I, Zugazagoitia J, Herbertz S, John W, Paz-Ares L, Schmid-Bindert G. KRAS-mutant non-small cell lung cancer: from biology to therapy. Lung Cancer. 2018 Oct 1;124:53-64.
  62. Miravalle L, Lefferts JA, Al-Haddad M, Tsongalis GJ, Cheng L. KRAS testing in clinical laboratory: optimizing targeted therapy. Cancer Genomics-Proteomics. 2012 Sep 1;9(5):337-41.
  63. Shajani-Yi Z, de Abreu FB, Peterson JD, Tsongalis GJ. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non–Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing. Neoplasia. 2018 Mar 1;20(3):256-62.
  64. Mogi A, Kuwano H. TP53 mutations in nonsmall cell lung cancer. BioMed Research International. 2011 Jan 18;2011.
  65. Zhao J, Han Y, Li J, Chai R, Bai C. Prognostic value of KRAS/TP53/PIK3CA in non small cell lung cancer. Oncology letters. 2019 Mar 1;17(3):3233-40.
  66. Black RC, Khurshid H. NSCLC: an update of driver mutations, their role in pathogenesis and clinical significance. Rhode Island Medical Journal. 2015 Oct 1;98(10):25. .
  67. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clinical Cancer Research. 2009 Jul 15;15(14):4554-60.
  68. Gautschi O, Milia J, Cabarrou B, Bluthgen MV, Besse B, Smit EF, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y. Targeted therapy for patients with BRAF-mutant lung cancer results from the European EURAF cohort. Journal of Thoracic Oncology. 2015 Oct 1;10(10):1451-7.
  69. Addeo A, Passaro A, Malapelle U, Banna GL, Subbiah V, Friedlaender A. Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer treatment reviews. 2021 May 1;96.
  70. Brambilla E, Gazdar A. Pathogenesis of lung cancer signalling pathways: roadmap for therapies. European Respiratory Journal. 2009 Jun 1;33(6):1485-97.
  71. Addeo A, Banna GL, Friedlaender A. KRAS G12C mutations in NSCLC: from target to resistance. Cancers. 2021 May 21;13(11):2541.
  72. Berke TP, Slight SH, Hyder SM. Role of reactivating mutant p53 protein in suppressing growth and metastasis of triple-negative breast cancer. OncoTargets and therapy. 2022;15:23.
  73. Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. The role of BRAF V600 mutation in melanoma. Journal of translational medicine. 2012 Dec;10(1):1-9.
  74. de Koning H, Meza R, Plevritis SK, ten Haaf K, Mushi VN, Jeon J, Erdogan S, Kong CY, Han SS, van Rosmalen J, Choi SE. Benefits and harms of computed tomography lung cancer screening programs for high-risk populations.
  75. Harris RP, Sheridan SL, Lewis CL, Barclay C, Vu MB, Kistler CE, Golin CE, DeFrank JT, Brewer NT. The harms of screening: a proposed taxonomy and application to lung cancer screening. JAMA internal medicine. 2014 Feb 1;174(2):281-6.
  76. Mazzone PJ, Sears CR, Arenberg DA, Gaga M, Gould MK, Massion PP, Nair VS, Powell CA, Silvestri GA, Vachani A, Wiener RS. Evaluating molecular biomarkers for the early detection of lung cancer: when is a biomarker ready for clinical use? An official American Thoracic Society policy statement. American journal of respiratory and critical care medicine. 2017 Oct 1;196(7):e15-29.
  77. Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, Shieh F, Tsai J, Vaks J, Current R, Lawrence HJ. Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. Journal of clinical pathology. 2013 May 1;66(5):381-5.
  78. Yamamoto G, Kikuchi M, Kobayashi S, Arai Y, Fujiyoshi K, Wakatsuki T, Kakuta M, Yamane Y, Iijima Y, Mizutani H, Nakajima Y. Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing. International journal of oncology. 2017 May 1;50(5):1579-89.
  79. Jing C, Mao X, Wang Z, Sun K, Ma R, Wu J, Cao H. Next generation sequencing based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her 2 and TP53 mutations in patients with non-small cell lung cancer. Molecular medicine reports. 2018 Aug 1; 18(2):2191-7.
  80. Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. The Korean journal of internal medicine. 2009 Mar;24(1):48.
  81. Tuononen, K., Mäki‐Nevala, S., Sarhadi, V.K., Wirtanen, A., Rönty, M., Salmenkivi, K., Andrews, J.M., Telaranta‐Keerie, A.I., Hannula, S., Lagström, S. and Ellonen, P., 2013. Comparison of targeted next‐generation sequencing (NGS) and real‐time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin‐fixed, paraffin‐embedded tumor material of non‐small cell lung carcinoma—superiority of NGS. Genes, Chromosomes and Cancer, 52(5), pp.503-511.
  82. Carter J, Tseng LH, Zheng G, Dudley J, Illei P, Gocke CD, Eshleman JR, Lin MT. Non-p. V600E BRAF mutations are common using a more sensitive and broad detection tool. American journal of clinical pathology. 2015 Oct 1;144(4):620-8.
  83. Labbé C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, Leighl NB. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung Cancer. 2017 Sep 1;111:23-9.
Personalized and Precision Medicine Journal
Volume 9, Issue 33 - Serial Number 33
Original article
Spring 2024
Pages 14-28

  • Receive Date 12 February 2024
  • Revise Date 06 April 2024
  • Accept Date 19 May 2024

Home

Publication Ethics

Guide for Authors

Submit Manuscript

Contact Us